JAX Expands Korean Collaboration Via Immuno-Oncology Center
This article was originally published in PharmAsia News
Following its partnership with Seoul National University for a cancer genomics project, the US-based Jackson Laboratory is expanding its collaboration with South Korea, this time by agreeing to set up a cancer immunotherapy research center with Ewha Womans University, supported by a government grant.
You may also be interested in...
Asia Deal Watch: RAPT And Hanmi Partner On CCR4 Antagonist Offering Potential In Multiple Cancer Types
RAPT can earn up to $108m in milestones plus sales royalties under the deal. BerGenBio, Piramal partner on developing AML therapy.
Hanmi Pharm is remaining upbeat after Sanofi’s decision to find another commercialization partner for efpeglenatide, saying it was the best strategy for the long-acting GLP-1 agonist given the strategic change in the big pharma’s diabetes strategy.
GemVax unveils positive topline results for South Korean Phase II study of novel peptide drug targeting patients with moderate to severe Alzheimer’s disease, raising hopes for the upcoming US trials.